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Liver-stage antigen 1 (LSA-1) is a potential vaccine candidate against preerythrocytic stages of malaria. We
report here the immunogenicity of linear synthetic constructs delineated as TH-cell determinants from the non-
repeat regions of Plasmodium falciparum LSA-1 in murine models and human subjects from areas where ma-
laria is endemic in Rajasthan State, India. Seven peptide constructs (LS1.1 to LS1.7) corresponding to pre-
dicted T-cell sites from both the N- and C-terminal regions and peptide LS1R from a repeat region of PfLSA-1
were synthesized to analyze the cellular immune responses. These linear peptides were also tested for humoral
responses in order to determine if there were any overlapping B-cell epitopes in the predicted T-cell sites. Most
peptides induced cellular responses in peptide-immunized BALB/c and C57BL/6 mice as measured by prolif-
eration and cytokine analysis. Cross-reactive T-cell recognition of P. falciparum-based peptides in Plasmodium
berghei-immune animals was evaluated, but only one peptide, LS1.2 (amino acids 1742 to 1760) triggered T-cell
proliferation and interleukin-2 and gamma interferon secretion in P. berghei-immune splenocytes of BALB/c
and C57BL/6 mice as well as in Thamnomys gazellae (natural host of P. berghei ANKA). In an enzyme-linked
immunosorbent assay with the peptides, only one peptide, LS1.1, was recognized by anti-P. berghei liver-stage
serum. Three peptides (LS1.1, LS1.2, and LS1.3) of the eight peptides tested in this study were recognized by
a relatively large percentage of P. falciparum-exposed human subjects; the reactivities ranged from ;45% for
LS1.3 to ;60% for LS1.1 and LS1.2. Interestingly, all of the eight putative T-cell determinants were also recog-
nized by the sera collected from malaria patients, although the response was variable in nature. These TH- and
B-cell epitopes may be of potential value for preerythrocytic antigen-based malaria subunit vaccine formulations.
Malaria continues to be the major cause of mortality and
morbidity in the most heavily populated area of the world. It is
estimated that there are 300 to 500 million new Plasmodium
infections and 2 to 5 million deaths annually due to malaria
(42). In the past few years, due to the development of drug
resistance in the malarial parasite and insecticide resistance in
the vector, malaria control programs have been severely im-
peded. These factors call for the development of a vaccine
against malaria for improving public health in the tropical
world. Immunization studies using irradiated sporozoites have
indicated that responses to preerythrocytic-stage antigens ex-
pressed by sporozoite and/or liver-stage parasites can provide
complete immunity both in rodents and humans (6, 10, 16, 19,
26, 32, 36). Naive human volunteers immunized by irradiated
sporozoites exhibit sterile immunity and develop a T-cell-pro-
liferative response to several preerythrocytic and blood stage
antigens (21). The complex life cycle of the malarial parasite
and the extensive variability among strains of the same Plas-
modium species dictate that an effective malaria vaccine will
probably require inducing protective antibodies as well as ef-
fector CD41 and CD81 T lymphocytes specific for variants of
multiple antigens expressed at different stages of the life cycle.
The Plasmodium falciparum liver stage antigen 1 (PfLSA-1)
gene encodes a protein of ;230 kDa and is expressed through-
out the liver schizogony (15, 20, 43). The protein is localized as
flocculent material within the parasitophorous vacuole, which
forms a stroma in which hepatic merozoites are released and
which may adhere to the merozoites. A homologue of PfLSA-1
in the Plasmodium berghei preerythrocyte parasite has been
characterized; it has been suggested that this homologue is
involved in the induction of protective immunity against mu-
rine malaria (2). The PfLSA-1 protein contains a large central
repeat region that is polymorphic in length and that is flanked
by relatively invariant nonrepeat N- and C-terminal regions
(43). Mice immunized with a PfLSA-1 peptide (EQQSDLEQ
ERLAKEKLQ) were protected against challenge with P. berg-
hei sporozoites. The antipeptide antibodies recognized P. berg-
hei LSA-2, and spleen cells from these protected mice killed
P. berghei-infected hepatocytes in vitro (20). Studies by Hill et
al. revealed the potential importance of PfLSA-1 as a vaccine
candidate by showing that a peptide, corresponding to amino
acids 1786 to 1794 of the PfLSA-1, bound to HLA B53, which
was found to be associated with resistance to severe malaria in
Gambians (17, 18). These and a few other studies have estab-
lished that the T- and B-cell epitopes in PfLSA-1 protein are
highly immunogenic in humans naturally exposed to malaria
and that the protein may be an important vaccine target anti-
gen (2, 11).
We have been interested in defining B- and T-cell epitopes
of major malaria vaccine target antigens for their inclusion in
subunit vaccine constructs (3, 7, 8, 9, 22, 23, 35). In the present
study, we have attempted to characterize TH-cell epitopes in
the nonrepeat portion of PfLSA-1 in mice and in humans. We
have initially used mice to analyze the T-cell responses to these
peptides in murine models; we then analyzed the cellular and
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humoral immune responses to these peptide epitopes in ma-
laria-exposed human subjects from areas of Rajasthan State in
India where malaria is endemic. One of the goals of the pres-
ent study was also to inquire if the results of immune responses
in murine models can serve as useful indicators for narrowing
down the number of peptides that need to be tested in human
studies.
MATERIALS AND METHODS
Experimental animals. Eight- to 12-week-old female, inbred BALB/c (I-Ad
I-Ed) and C57BL/6 (I-Ab I-Eo) mice were purchased from IFFA CREDO, Brus-
sels, Belgium, and the small-animal facility of the National Institute of Immu-
nology, New Delhi, India. Breeding and maintenance of the natural host of P.
berghei ANKA, Thamnomys gazellae, were performed in the experimental animal
house of Prince Leopold Institute of Tropical Medicine, Antwerp, Belgium. All
the experimental animals were housed, fed, and used in the experiments in
accordance with guidelines set forth in the National Institutes of Health manual
“Guide for the Care and Use of Laboratory Animals” (29).
Synthetic peptides. The procedures employed for synthesis, purification, and
characterization of the synthetic constructs used in this study were essentially the
same as those described in our earlier work (3, 7, 8, 9, 22, 23, 35). Briefly,
peptides were synthesized by a stepwise solid-phase procedure (Boc-chemistry)
using an automated peptide synthesizer (model 430A; Applied Biosystems, Fos-
ter City, Calif.). Peptides were purified by gel filtration with Sephadex G-25,
followed by reverse-phase high-performance liquid chromatography on a m-
Bondapak C18 column (Waters Associates, Milford, Pa.). The identity and purity
of peptides were confirmed by amino acid analysis and in some cases also by
sequencing on an automated peptide sequencer (model 477A; Applied Biosys-
tems). Lyophilized peptides were dissolved in ultrapure water and stored frozen
at 220°C, and their serial dilutions in the culture medium were prepared imme-
diately before each assay. The sequences of these peptide constructs are shown in
Fig. 1.
Immunization of experimental animals with synthetic peptides. Groups of
BALB/c and C57BL/6 mice were immunized once with 40 to 60 mg of peptide per
mouse, emulsified 1:1 (vol/vol) in complete Freund’s adjuvant (CFA) containing
the bacterial strain H37Ra (Difco Laboratories, Detroit, Mich.) by injecting
subcutaneously at the tail base and hind footpad. As a control, groups of naive
and phosphate-buffered saline (PBS; emulsified 1:1 in CFA)-immunized mice
were included in the study.
P. berghei ANKA-immune animals. Immune C57BL/6 mice were obtained
after three intravenous injections, spaced 14 days apart, of 30,000 g-irradiated
sporozoites each (12,000 rads, 60Co source). Immune BALB/c mice and T.
gazellae animals were obtained by single injections of 10,000 g-irradiated sporo-
zoites each.
Cell culture medium. For human peripheral blood mononuclear cell (PBMC)
preparation, modified McCoy’s 5A medium (Life Technologies, Inc., Grand
Island, N.Y.) supplemented with 10% normal AB1 human serum (donors not
previously exposed to malaria), 2 mM L-glutamine, 25 mM HEPES, 0.2%
NaHCO3, 1% antibiotic/antimycotic solution (1003), and 0.1 mM minimal es-
sential medium (MEM) nonessential amino acid solution was used. RPMI 1640
medium supplemented with 10% fetal calf serum (FCS), 50 mM b-mercapto-
ethanol, 2 mM L-glutamine, 25 mM HEPES, 0.2% NaHCO3, 1% antibiotic/
antimycotic solution (1003), and 0.1 mM MEM nonessential amino acid solution
was used for the mouse lymphocyte proliferation assay. For hepatocyte prepa-
ration, MEM supplemented with 5% FCS and 1% penicillin-streptomycin was
used.
Generation of anti-P. berghei liver-stage sera. A six-week-old BALB/c mouse
previously irradiated at 800 rads from a 60Co source was infected with 2 million
P. berghei sporozoites via the intravenous route in the tail vein. Twenty-four
hours later, the liver was removed aseptically from the infected mouse and
hepatocytes were prepared by collagenase perfusion. Liver fragments were per-
fused with 50 ml of 1 mM HEPES buffer, followed by 50 ml of the same buffer
containing 0.05% collagenase (Sigma Chemical Co., St. Louis, Mo.) and 5 mM
CaCl2. All solutions were maintained at 37°C during the perfusion process. The
distended liver pieces were teased in HEPES buffer, and the released cells were
filtered and then washed three times. The cell pellet was suspended in complete
MEM. Hepatocyte viability was assessed by light microscopy.
One million infected hepatocytes were injected intravenously via the tail vein
into 10 naive BALB/c mice. Two weeks later, sera were collected from all im-
munized mice, pooled together, aliquoted, and frozen at 220°C until further use.
Murine spleen and lymph node T-cell proliferation assay. All immunized and
control mice were sacrificed after 10 to 12 days of immunization by cervical
dislocation. The spleen and lymph nodes (inguinal and popliteal) were asepti-
cally removed, and cell suspensions were made. Cells were washed three times
with serum-free RPMI 1640 medium and then cultured in a flat-bottom 96-well
plate (Falcon; Becton Dickinson, Lincoln Park, N.J.) at a concentration of 5 3
105 cells per well in complete RPMI 1640 medium. Appropriate peptides were
incubated with the seeded lymphocytes at different concentrations. All cultures
were set up in quadruplicate, and the plates were incubated at 37°C and 5% CO2
in a humidified chamber. As a positive control concanavalin A (Sigma), at a
previously determined optimal concentration of 5 mg/ml, was used as a nonspe-
cific polyclonal mitogen. After 48 (concanavalin A) or 100 h (synthetic peptides),
cultures were pulsed with 1 mCi of [methyl-3H]thymidine (Amersham Interna-
tional, Buckinghamshire, United Kingdom)/well for 12 h. The cells were then
harvested onto glass fiber filters by using the PHD cell harvester (Cambridge
Technology, Inc., Watertown, Mass.), and the [3H]thymidine incorporation was
determined by b-emission liquid scintillation spectroscopy (Betaplate; Pharma-
cia, Uppsala, Sweden). The geometric mean of the counts per minute for each set
of quadruplicate wells was calculated, and the stimulation index (SI) was deter-
mined as the geometric mean counts per minute of the peptide-stimulated
culture divided by the geometric mean counts per minute of the unstimulated
culture (background). The standard deviations in all cases never exceeded 20%
of the means. An SI value of 2.0 was considered as the cutoff value.
Study sites and human subjects. Two rural areas of high endemicity in the
Rajasthan state were investigated: Jodhpur and Udaipur. Donors ranged in age
from 12 to 57 years and were of both sexes. Informed consent from all the human
subjects was obtained after explaining to them the objectives of the study in
detail, particularly emphasizing the fact that the study was approved by the
institutional Human Volunteers Research Ethical Committee of the Interna-
tional Centre for Genetic Engineering and Biotechnology, New Delhi, India.
(i) Sample collection for humoral responses. A total of 61 serum samples were
collected from P. falciparum-infected human subjects admitted to the local hos-
pitals of rural areas of Jodhpur and Udaipur city. All these patients presented
with characteristic symptoms of high fever, chill, and rigor. Blood for serum
collection from these patients was generally obtained 2 weeks after the comple-
tion of drug treatment. For negative control, serum samples were also collected
from 10 healthy individuals who had no known past history of malaria and who
were negative for malaria by slide examination at the time of drawing blood.
With the P. falciparum lysate used as the capture antigen, these sera (each
diluted 1/200) yielded an average optical density at 490 nm (OD490) of 0.28 with
a standard deviation (SD) of 0.036 by enzyme-linked immunosorbent assay
(ELISA). With the synthetic peptide constructs in the same assay, these sera gave
average OD490s (6 SD) of 0.012 6 0.013 (LS1.1), 0.010 6 0.009 (LS1.2), 0.007 6
0.005 (LS1.3), 0.007 6 0.009 (LS1.4), 0.008 6 0.008 (LS1.5), 0.016 6 0.008
(LS1.6), 0.025 6 0.020 (LS1.7), and 0.023 6 0.011 (LS1R).
(ii) Sample collection for lymphocyte transformation assay. For the analysis of
T-cell responses, peripheral blood samples from 22 confirmed P. falciparum-
infected patients who had recovered from their last malaria episodes about 10 to
14 weeks prior to study were collected under medical supervision. Samples of 10
to 15 ml of venous blood were obtained in sterile tubes containing citrate-
phosphate-dextrose (CPD) with McCoy’s 5A medium (GIBCO BRL, Grand
Island, N.Y.). To determine whether PfLSA-1 peptides stimulated proliferation
and cytokine production by lymphocytes from persons not sensitized to the
malaria antigen, blood was also obtained from seven healthy donors who had
never been exposed to malaria. All the blood samples from human volunteers
were malaria parasite negative by slide examination at the time of sample col-
lection, and the volunteers gave informed consent to participate in this study.
Preparation of human PBMC and lymphocyte transformation assay. Blood
samples were collected aseptically in CPD tubes in the field and transported in
ice to the laboratory within 6 h. The PBMC were isolated on a density gradient
(Histopaque-1077; Sigma Chemical Co.) by centrifugation. Briefly, a 50-ml cen-
trifuge tube containing 10 ml of Histopaque was loaded with 10 to 15 ml of donor
blood and centrifuged at 1,800 rpm (400 3 g) for 20 min at room temperature.
FIG. 1. (a) Schematic representation of P. falciparum LSA-1; (b) sequences
of peptides used in this study. All the peptides represent amino acid sequences
deduced from the genetic sequence of the P. falciparum NF54 isolate.
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The PBMC at the interphase were collected, washed three times in 0.9% normal
saline, and resuspended in complete McCoy’s 5A culture medium. Viable PBMC
counts were made under a phase-contrast microscope by the trypan blue dye
exclusion test.
A total of 2 3 105 to 3 3 105 PBMC in 100 ml of culture medium were plated
in a 96-well flat-bottom plate with various concentrations of PfLSA-1 synthetic
constructs and cultured in triplicate wells for 6 days in a humidified atmosphere
with 5% CO2 at 37°C. Control cultures received 100 ml of culture medium
(background), 100 ml of control peptide (hen egg lysozyme [HEL]; 20 mg/ml),
and 100 ml of phytohemagglutinin (PHA); 5 mg/ml; Sigma). After 96 h of
stimulation, 100 ml of cell-free supernatant was removed from each well, saved
for the estimation of gamma interferon (IFN-g) concentration, and replaced with
100 ml of complete culture medium. In the 6 days of culture, the cells were pulsed
with 1 mCi of [methyl-3H]thymidine (Amersham International)/well during the
last 16 h. The cells were then harvested onto glass fiber filters by using the PHD
cell harvester (Cambridge Technology, Inc.), and the [3H]thymidine incorpora-
tion was determined by b-emission liquid scintillation spectroscopy (Betaplate;
Pharmacia). Results were expressed as SI, and a positive lymphoproliferative
response was determined as being one in which SI was .2 (mean counts per
minute of test cultures . mean counts per minute of control cultures 1 2 SD of
the control mean). As a control, PBMC from individuals with no history of
exposure to malaria were included in each set of experiments.
Measurement of lymphokines in the culture supernatants. For the analysis of
lymphokines in the culture supernatants of in vitro-stimulated murine lymph
node cells, culture supernatants were collected after 48 (for interleukin-2 [IL-2]
analysis) and 96 h (for IFN-g and IL-4 analysis) of antigen stimulation. In the
similar way, culture supernatants from stimulated human PBMC were also col-
lected and pooled for IFN-g measurement after 96 h of stimulation. All these
lymphokines were measured by using a murine and human cytokine immunoas-
say kit (Genzyme Corp., Cambridge, Mass.) following the procedure provided by
the manufacturer. An anti-rat IFN-g detection ELISA kit (Cell Biology Prod-
ucts, GIBCO BRL, Gaithersburg, Md.) was utilized for the detection of IFN-g in
the culture supernatants of P. berghei-immunized T. gazellae spleen cells stimu-
lated with PfLSA-1 peptides.
Measurement of antibody responses by ELISA. Antibody titers against
PfLSA-1 peptides in mouse and human sera were determined by the standard
ELISA method as described previously. Briefly, flat-bottom Immulon-2 ELISA
plates (Dynatech Laboratories Inc., Chantilly, Va.) were coated at 4°C overnight
with 100 ml of capture antigen (10 mg of synthetic peptide/ml) in PBS (0.01 M;
pH 7.2) and then washed with PBS and 0.05% Tween-20 (PBS-T). The uncov-
ered reactive sites in the wells were blocked by incubation with a 5% solution of
non-fat dried milk powder in PBS. All sera to be tested were diluted 1/200
(human sera) and 1/100 to 1/12,800 (anti-liver-stage sera from BALB/c mouse) in
PBS containing 0.1% nonfat dried milk powder and incubated in the capture
antigen-coated wells for 4 h at room temperature in a humid chamber. The
unbound antibodies were washed off with PBS-T. The horseradish peroxidase-
conjugated goat anti-mouse immunoglobulin G (IgG) or goat anti-human IgG
(Sigma) was used at a 1:1,000 dilution as the second antibody in the respective
assays. The plates were incubated further for 90 min in a humid chamber and
then washed with PBS-T. The enzyme reaction was developed with o-phenyl-
enediamine dihydrochloride as the chromogen and hydrogen peroxide as the
substrate. After the reaction was stopped with 8 N sulfuric acid, the OD490 of the
reaction product in the wells was recorded by using a Microplate reader (Mo-
lecular Devices, Palo Alto, Calif.). The cutoff value for a positive response was
defined as an OD greater than or equal to the mean plus 2 SD of sera from 10
human donors who had never been exposed to malaria.
RESULTS
Analysis of T-cell responses and cytokine profile in murine
models. We analyzed the complete PfLSA-1 sequence for am-
phipathicity (25) and identified several sequences which may
represent immunodominant TH-cell antigenic sites. Seven syn-
thetic peptides from the nonrepeat N- and C-terminal regions
of PfLSA-1 were selected and synthesized (Fig. 1). Peptide LS1R,
representing the PfLSA-1 repeat sequence, was also synthe-
sized. In order to determine the abilities of individual peptides
to prime murine T cells, groups of BALB/c and C57BL/6 mice
were immunized with each peptide emulsified with CFA. After
10 to 12 days, draining lymph node T cells were stimulated with
the respective peptide at various concentrations. The results of
T-cell proliferation are presented as the maximum SI obtained
at a given peptide concentration (5 to 40 mg/ml) in three
separate experiments. Cytokines (IL-2, IFN-g, and IL-4) anal-
ysis was carried out with the pooled culture supernatants col-
lected from all three separate experiments. We observed di-
verse T-cell proliferative responses and cytokine production
levels for each peptide (Fig. 2 and Table 1). As shown in Fig.
2b to d, peptides LS1.2, LS1.3, and LS1.4 induced T-cell pro-
liferation in both strains of mice, although the intensity of the
immune response varied; peptide LS1.2 induced more prolif-
eration in C57BL/6 (maximum SI: 19.5) than in BALB/c mice
(maximum SI: 3.6), while LS1.3 induced more proliferation in
BALB/c (maximum SI: 18.3) than in C57BL/6 mice (maximum
SI: 5.5). Peptide LS1.4 induced similar levels of T-cell prolif-
eration in both strains of mice (maximum SI: ;3). The im-
mune responses induced by some peptides were genetically
restricted; peptides LS1.5 (Fig. 2e) and LS1R (Fig. 2h) induced
T-cell responses only in BALB/c mice (maximum SIs: 4.8 and
10.9, respectively), whereas peptide LS1.1 (Fig. 2a) induced a
strong T-cell response only in C57BL/6 mice (maximum SI:
9.9). Only peptide LS1.6 (Fig. 2f) did not induce any T-cell
proliferation in either of the strains of mice (SI: ,2). In control
naive and adjuvant-immunized mice, no T-cell proliferation
was observed at any concentration of the peptides, which ruled
out the possibility of mitogenic activity or contamination in
peptides (data not shown). Further, in order to determine the
TH1/TH2 profile of the lymphocyte proliferation, levels of IL-2,
IFN-g, and IL-4 secretion in culture supernatants were ana-
lyzed with mouse cytokine ELISA kits (see Materials and
Methods). The supernatants were collected from lymphocyte
cultures after 48 (for IL-2 estimation) and 96 h (for IL-4 and
IFN-g estimation) of incubation following in vitro peptide
stimulation. As shown in Table 1, only peptide LS1R induced
the secretion of both TH1- (IL-2 and IFN-g) and TH2 (IL-4)-
derived cytokines in BALB/c mice. Peptides LS1.1, LS1.2, and
LS1.3 induced a significant amount of IL-2 and IFN-g in both
BALB/c and C57BL/6 mice but no IL-4, indicating that a
TH1-type subset is involved in the recognition of these pep-
tides. Peptide LS1.4 induced a low level of IL-2 and IFN-g
secretion in both the strains of mice, while LS1.5 induced a low
level of IL-2 and IFN-g in only BALB/c mice. Stimulation of
lymph node cells with peptides LS1.6 and LS1.7 did not induce
secretion of any of the three cytokines at any concentration of
the peptides (Table 1).
Since a PfLSA-1 homologue in P. berghei has been described
(2), we also investigated if any of the PfLSA-1-derived peptides
were able to cross-stimulate the T cells from P. berghei-exposed
mice. A group of BALB/c and C57BL/6 mice were immunized
by injecting g-irradiated P. berghei ANKA sporozoites. As a
natural host for P. berghei ANKA, T. gazellae mice were also
included in this study. In a lymphoproliferation assay using
splenocytes of P. berghei ANKA-immune mice, only peptide
LS1.2 was able to induce a positive T-cell response (SI .2) in
both the strains of mice (Fig. 3). Peptide LS1R also induced a
positive proliferative response in P. berghei ANKA-immune
splenocytes of BALB/c mice (maximum SI: 2.25) but not in
C57BL/6 mice (Fig. 3). Likewise, immune T. gazellae spleno-
cytes were able to recognize only the peptide LS1.2 (maximum
SI: 4.3) in a T-cell proliferation assay (Table 2). In this exper-
iment, peptide LS1.2 was able to induce a substantial amount
of IFN-g (28 U/ml) in the culture supernatants after 96 h of
stimulation. On the other hand, peptide LS1R induced IFN-g
secretion without any T-cell proliferation. Splenocytes from
the naive control animal did not proliferate or secrete IFN-g
when stimulated with any of the eight peptides (Table 2).
Recognition of PfLSA-1-derived peptides by anti P. berghei
liver-stage sera. T-cell epitope sequences in malaria antigens
often overlap with B-cell determinants (3, 4, 7, 11, 13, 22, 35).
In order to find out if any of the synthetic peptides represent-
ed cross-reactive B-cell epitopes in P. berghei infection, anti-
P. berghei liver-stage serum was generated in BALB/c mice as
described in Materials and Methods. Antibody reactivity to syn-
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FIG. 2. Lymph node T-cell proliferative responses in BALB/c and C57BL/6 mice immunized with PfLSA-1-based synthetic peptides. All mice were immunized with
60 to 70 mg of peptide in CFA, and 10 to 12 days later cells from the draining lymph nodes were cultured for 100 h with various concentrations of homologous peptides.
Concanavalin A (5 mg/ml) was used as a positive control. All values are means of quadruplicate determinations with standard deviations not more than 20% of the
means. The results are expressed as SIs, defined as counts per minute in stimulated cultures divided by counts per minute in unstimulated cultures. An SI value of more
than 2.0 was scored as positive result. Background counts per minute ranged from 235 to 5,560 for BALB/c mice and from 160 to 6,446 for C57BL/6 mice in all cases.
The results shown are from three experiments performed separately, and results are expressed as maximum SI obtained at a given peptide concentration.
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thetic peptides was assessed by ELISA using serum dilutions
from 1:100 to 1:12,800. As shown in Fig. 4, only peptide LS1.1
was recognized by anti-P. berghei liver-stage serum (OD490:
0.17 at 1:12,800). All the other seven PfLSA-1-based peptides
did not show any significant reactivity with anti-P. berghei liver-
stage serum.
Analysis of T-cell responses and IFN-g production in hu-
man subjects exposed and not exposed to P. falciparum. Pro-
liferative responses of the malaria-exposed human T cells and
IFN-g secretion in response to each of the PfLSA-1-based syn-
thetic peptides were studied. Blood samples from 22 P. falci-
parum-exposed human donors and seven nonexposed control
donors were collected. In all the lymphoproliferation assays,
subjects who showed SIs of .2 were considered positive re-
sponders. There were individual variations in the pattern of
response to the different concentrations of peptides used.
Some subjects responded at lower concentrations of peptides
(2.5 and 5 mg/ml), while a higher concentration (10 or 20 mg/
ml) was required to induce a maximal response in other do-
nors. Therefore, the individuals who showed SIs .2 for at least
one of the four concentrations of peptides were scored as
positive responders. Nonspecific polyclonal T-cell mitogen PHA
(5 mg/ml) and a synthetic peptide from HEL (HEL46–61; NTD
GSTDYGILQINSR) were used as the positive and negative
controls, respectively, in these experiments. All the donors
tested in this study exhibited a positive response to PHA (mean
SI: 21.9; maximum SI: 52). On the other hand, except for
donors 6 (SI: 2.8) and 11 (SI: 2.2), the donors did not respond
to the control peptide, HEL46–61. The results from these stud-
ies are summarized in Fig. 5. Specific lymphoproliferative re-
sponses were observed for all the PfLSA-1-derived peptides,
but the extent of the response varied in different individuals.
We found that peptides LS1.1 and LS1.2 represented the most
widely recognized T-cell epitopes, both inducing a proliferative
response in as many as 59% of the individuals (13 of 22 tested),
followed by LS1.3, which was recognized by ;45% of P. falci-
FIG. 3. Proliferative responses in P. berghei-immune splenocytes of BALB/c
and C57BL/6 mice. Immune mice were obtained after immunization with irra-
diated P. berghei sporozoites. Immune splenocytes were stimulated with PfLSA-
1-based peptides ex vivo at a concentration of 20 mg/ml. The results were
expressed as SIs, and a value of more than 2.0 was scored as a positive result.
Background counts per minute were 5,336 and 3,136 for BALB/c and C57BL/6
mice, respectively. The results shown are from a representative experiment
performed more than three times.
TABLE 1. Cytokine analysisa of culture supernatants of murine
lymph node cells after in vitro stimulation with
PfLSA-1-derived synthetic peptides
Peptide Peptide concn(mg/ml)
Secretion of indicated cytokine (pg/ml) by:
BALB/c mice C57BL/6 mice
IL-2 IFN-g IL-4 IL-2 IFN-g IL-4
LS1.1 0 ,5 75 ,5 40 ,10 ,5
10 120 180 ,5 360 9,800 ,5
20 120 360 ,5 260 5,600 ,5
40 260 1,500 ,5 280 1,200 ,5
LS1.2 0 40 100 ,5 80 60 ,5
10 160 800 ,5 400 10,400 ,5
20 180 660 ,5 360 8,800 ,5
40 90 160 ,5 440 9,200 ,5
LS1.3 0 70 120 ,5 15 ,10 ,5
10 360 600 ,5 18 135 ,5
20 180 3,000 ,5 30 540 ,5
40 135 10,200 ,5 30 675 ,5
LS1.4 0 50 120 ,5 8 ,10 ,5
10 180 450 ,5 18 1,440 ,5
20 165 600 ,5 30 600 ,5
40 135 1,560 ,5 8 510 ,5
LS1.5 0 60 ,10 ,5 10 ,10 ,5
10 165 120 ,5 15 ,10 ,5
20 225 180 ,5 18 45 ,5
40 165 45 ,5 15 30 ,5
LS1.6 0 ,5 ,10 ,5 ,5 ,10 ,5
10 ,5 ,10 ,5 ,5 ,10 ,5
20 ,5 ,10 ,5 ,5 ,10 ,5
40 ,5 ,10 ,5 ,5 ,10 ,5
LS1.7 0 ,5 ,10 ,5 ,5 ,10 ,5
10 ,5 ,10 ,5 ,5 ,10 ,5
20 ,5 ,10 ,5 ,5 ,10 ,5
40 ,5 ,10 ,5 ,5 ,10 ,5
LS1R 0 ,5 ,10 ,5 ,5 ,10 ,5
10 45 525 75 ,5 ,10 ,5
20 60 705 85 ,5 ,10 ,5
40 135 840 240 ,5 ,10 ,5
a Cytokine analysis was performed by using specific murine cytokine ELISA
kits. Data analysis was done with the respective standard cytokine curves.
TABLE 2. Lymphoproliferation and IFN-g secretion by naive and
P. berghei-immune T. gazellae splenocytes upon in vitro
stimulation with PfLSA-1-derived peptides
Stimulanta
SI for indicated
lymphocytes IFN-g secretion
(U/ml)b
Naive Immune
LS1.1 0.6 1.2 ,5
LS1.2 1.3 4.3 28
LS1.3 0.8 1.2 ,5
LS1.4 0.75 0.8 ,5
LS1.5 0.6 0.75 ,5
LS1.6 0.86 0.7 ,5
LS1.7 1.4 0.75 ,5
LS1R 0.9 1.1 12
a Splenocytes were stimulated with various peptides at the final concentration
of 20 mg/ml.
b IFN-g analysis was done only with culture supernatants of P. berghei-immune
splenocytes by using a rat IFN-g ELISA kit. The IFN-g concentration in the
control culture (no antigen) supernatant was always ,5 U/ml.
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parum-exposed donors (10 of 22 tested). The mean SIs for
LS1.1, LS1.2, and LS1.3 were 5.84, 3.17, and 5.54 respectively,
while maximum SIs for these peptides were 42.0, 10.6, and
42.0, respectively. The PBMC of 40% of exposed donors were
able to recognize peptide LS1.4, while peptide LS1.5 was rec-
ognized by only ;27% of malaria-exposed donors. Peptides
LS1.6, LS1.7, and LS1R were relatively poorly recognized; only
;13 to 18% of donors responded to these peptides (Fig. 5).
Although SIs for most of the positive responders were between
2 and 5, SIs for some donors were higher than 10 with peptides
LS1.1, LS1.2, and LS1.3. Except for one control donor (CON2),
who responded weakly to peptides LS1.1 (SI: 2.4) and LS1.2
(SI: 2.6), none of the nonexposed donors responded to any of
the peptides.
Due to the known susceptibility of the liver stages of the
malaria parasite to IFN-g (27), produced as a result of cellular
responses to the parasite antigens, the ability of human PBMCs
to secrete this cytokine in response to PfLSA-1-based peptide
stimulation was also assessed. The supernatants were collected
after 96 h of stimulation, and IFN-g levels in the samples were
measured at the antigen concentration at which the maximum
proliferation was observed. The IFN-g secretion was assessed
by comparison with control culture supernatant without anti-
gen (mean IFN-g concentration: 180 6 20 pg/ml). A value of
.400 pg of IFN-g secretion/ml was considered positive. Over-
all, positive responses were detected in a large proportion of
infected individuals, ranging from a minimum of 18.1% for
peptide LS1.7 to a maximum of 53.3% for peptide LS1.2. The
highest mean IFN-g production was 2,056 6 566 pg/ml in
response to peptide LS1.2, followed by 1,501 6 513 pg/ml when
stimulated with peptide LS1.1 (Fig. 5). In some cases, however,
production of IFN-g was observed even when no T-cell prolif-
eration occurred. On the other hand, the reverse was also
observed, i.e., T-cell proliferation followed by no IFN-g pro-
duction. Also, as shown in Fig. 5, few control donors’ PBMC
were able to secrete IFN-g without any lymphoproliferation.
This is in accordance with previously described studies with
PfLSA-1-based peptides (11, 20).
Humoral responses in P. falciparum-exposed human donors.
A total of 61 serum samples, including those collected from
exposed donors which were used in T-cell proliferation exper-
iments, were analyzed to assess antibody responses against
PfLSA-1-based synthetic peptides. The positive responders
were defined as those who showed an OD490 value in an
ELISA above the mean 1 2 SD of 10 normal control sera when
reacted with PfLSA-1-based synthetic peptides (see Materials
and Methods). The normal control sera were obtained from
volunteers who had no history of malaria infection. We found
that all the eight peptides were recognized, to various degrees,
by circulating IgG antibodies in the sera of human subjects
recovering from natural P. falciparum infection. As shown in
Fig. 6, synthetic peptides LS1.2, LS1.3, and LS1.5 were more
widely recognized (45 to 65% positive responders) than the
others. Peptide LS1.7 was the most poorly recognized; only
;8% of the malaria-exposed sera reacted with this peptide.
A synoptic summary of the humoral and cellular immune
responses in twenty-two malaria-exposed individuals against
PfLSA-1-derived peptides is presented in Table 3. There seems
to be a correlation between the humoral and cellular responses
in malaria-exposed donors to most of the synthetic peptides.
On the other hand, peptides LS1R and LS1.6 appear to be
poor T-cell epitopes and reasonably good B-cell epitopes. The
correlation between cellular and humoral immune responses
for each malaria-exposed donor is also shown in Fig. 5. Most of
the P. falciparum-exposed donors who showed positive cellular
responses also exhibited a positive antibody response, indicat-
ing a noticeable correlation between B- and T-cell responses
and IFN-g secretion (r . 0.729).
DISCUSSION
T cells play a crucial role in malaria immunity both by reg-
ulating antibody production and mediating antibody-indepen-
dent cellular effector mechanisms (28). Epidemiological stud-
ies in areas of endemicity are required to collect information
about antibody and T-cell immune responses against defined
parasite molecules during natural sensitization against malaria.
In the present study, we have attempted to characterize T-cell
determinants in the nonrepeat regions of PfLSA-1 by using
synthetic peptides in mice and in P. falciparum-exposed human
subjects living in an area in India where malaria is endemic.
Results of T-cell proliferation studies with two different strains
of mice showed that of the eight predicted T-cell epitope
sequences, at least four peptides (LS1.2, LS1.3, LS1.4, and
LS1.7) induced T-cell responses in both the strains of mice.
Peptides LS1.5 and LS1R induced lymphoproliferation only in
BALB/c mice, while peptide LS1.1 was able to induce substan-
tial T-cell proliferation only in C57BL/6 mice. Results of mea-
surements of cytokines released upon in vitro stimulation of
peptide-primed T lymphocytes with homologous peptides by
and large supported the proliferation data. Analysis of cyto-
kines in the culture supernatants of peptide-induced lympho-
cytes demonstrated that most of the PfLSA-1-based peptides
induced the TH1-type subset to secrete IL-2 and IFN-g but did
not activate the TH2-type subset to secrete IL-4. Only peptide
LS1R induced both the TH1 and TH2 types of T cells. Similar
observations were made by White et al., who found that im-
munization with P. berghei sporozoites induced T cells that
secreted IL-2 and IFN-g but not IL-4 (40). It has also been
proposed that P. berghei sporozoite-induced TH1 cells play a
central role in the induction of effector CD81 T cells and
possibly also in the regulation of TH2 cells secreting IL-4 (40).
FIG. 4. Reactivity of anti-P. berghei liver-stage serum antibodies to PfLSA-
1-based peptides in an ELISA. Anti-P. berghei liver-stage sera were generated by
injecting 1 million infected hepatocytes intravenously into a group of 10 naive
BALB/c mice. Two weeks later, sera were collected from all immunized mice and
pooled together. Negative-control values were obtained by incubating peptides
with normal mouse serum antibodies and did not exceed an OD of 0.02.
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Thus, cytokines secreted by T cells after activation qualitatively
influence the nature of the immune response. However, it is
not clear from our experiments why mostly TH1-biased T-cell
subsets are induced upon immunization with these peptides.
There could be several factors responsible for the observed
polarized TH1 response, which include the dose and nature of
the antigen, antigen-presenting cells, antigen processing and
presentation pathways, and costimulatory molecules involved
in activation (34, 41). We did not explore this any further.
Taken together, our results indicate that all PfLSA-1-based
predicted T-cell epitopes, except LS1.6, on their own can gen-
erate memory T cells, which proliferate in vitro upon stimula-
tion with the homologous peptide. However, at the same time
it is clear that the cellular response to synthetic peptides is
genetically restricted, at least to some extent, suggesting that
using a single strain, for example BALB/c mice, as an initial
screen for selecting T-cell sequences may not always be ade-
quate.
Earlier studies have suggested the presence of a PfLSA-1
homologue in P. berghei, and mice immunized with PfLSA-1-
FIG. 5. PBMC proliferation and IFN-g responses in P. falciparum-exposed human subjects and nonexposed control donors. Blood was collected during the
convalescence period, since the in vitro cellular response to parasite antigens is diminished during acute infections (30, 33, 38). Results are expressed as SIs, and only
the maximum SI obtained at any of the peptide concentrations used is taken into consideration. Proliferative responses were considered positive if the SI was more
than 2. h, negative response (SI , 2); z, positive response with 2 , SI , 5; n , positive response with SI . 5. For IFN-g: h, negative response; s, positive response
(IFN-g concentration in culture supernatant . 400 pg/ml). Mean IFN-g production in the culture supernatants of control cultures (without antigen) of all donors was
180 6 20 pg/ml. For antibody response: h, negative; n , positive. PBMC from control individuals with no known history of malaria were tested in parallel (CON1 to
CON7). As negative and positive controls, an unrelated TH epitope from HEL and PHA, respectively, were included in the study at single concentrations of 20 and
5 mg/ml, respectively. Background count-per-minute ranges: for malaria exposed donors, 69 to 3,480 (geometric mean 5 378 cpm); for control donors, 190 to 911
(geometric mean 5 480 cpm). We summarized the results only from malaria-exposed individuals. n.d., not determined; Sum., summary; % 1 Ve, percent positive.
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based peptide sequences were protected against heterologous
challenge with P. berghei sporozoites (2). It was thus appealing
to probe whether any of the PfLSA-1-based synthetic peptides
would cross-react with T lymphocytes from mice exposed to P.
berghei sporozoites. We found that at least one of the peptides
(LS1.2) triggered the stimulation of splenocytes obtained from
mice immunized with irradiated P. berghei sporozoites, sug-
gesting that during immunization, memory T cells cross-react-
ing with the PfLSA-1 peptide were generated; these T cells are
later expanded upon restimulation with the specific LS1.2 se-
quence. The only other peptide that showed cross-reactivity at
the T-cell level was the repeat-based peptide LS1R, but the
response was genetically restricted to the BALB/c (IAd IEd)
strain of mice. Essentially similar results were obtained when
P. berghei-primed splenocytes from T. gazellae, a natural host of
P. berghei, were stimulated in vitro with the synthetic peptides;
only LS1.2 showed cross-reactivity in terms of lymphoprolif-
eration and IFN-g secretion in the culture supernatants. These
results show that LS1.2 represents an immunodominant and
cross-reactive T-cell epitope in the C-terminal region of PfLSA-1.
Since several T-cell determinants in malaria antigens are
known to overlap with B-cell determinant sequences (3, 4, 11,
20), we wondered if any of the synthetic peptides in the present
study also represented cross-reactive B-cell epitopes. Results
of ELISA carried out with anti-P. berghei liver-stage serum
revealed that only one peptide (LS1.1) represented a P. berghei
ross-reactive B-cell epitope. Interestingly, peptide LS1.2, which
showed cross-reactivity at the T-cell level, showed no reactiv-
ity with P. berghei-infected mouse serum. Likewise, the repeat-
based peptide LS1R, which showed cross-reactivity at the T-
cell level, also did not react with the anti-P. berghei liver-stage
serum. The repeat-based peptide sequences have been de-
scribed as B-cell epitopes in humans (20). These results suggest
that peptides LS1.1 and LS1.2 may represent sequences that
are similar to those in the putative P. berghei LSA-1 or even
perhaps in some other P. berghei antigens. However, how these
peptides with no apparent sequence homology can cross-react
both at the T-cell and B-cell levels is well established (1, 21,
39).
In order to find out if PfLSA-1-based peptides that induced
cellular immune responses in mice also represent T-cell deter-
minants in humans exposed to P. falciparum infection, we an-
alyzed blood samples from an area in India where malaria is
endemic. Earlier studies have reported the presence of TH and
cytotoxic T lymphocyte (CTL) epitopes in PfLSA-1 in malaria-
exposed human subjects. For example, an immunodominant
HLA B53-restricted CTL epitope, described by Hill et al., in a
Gambian population was found to be associated with resis-
tance to severe malaria (18). Other studies characterized sev-
eral TH epitopes, mainly in the C-terminal domain of PfLSA-1,
in the sporozoite-immunized human volunteers (24) and ma-
laria-infected human subjects, including sequence overlapping
LS1.1, and LS1.5 (11, 20). Results of the present study showed
that the T cells from a large proportion of human donors
exposed to malaria proliferated in response to PfLSA-1-based
peptides. Similar to what was found in the murine model, pep-
tides LS1.1, LS1.2, LS1.3, and LS1.4 represented immunodom-
inant T-cell epitopes in humans. Although, we did not carry
out the HLA typing of the infected donors, broad recognition
of PfLSA-1 peptides, particularly with LS1.1, LS1.2, LS1.3, and
LS1.4, may indicate a lack of genetic restriction and the pres-
ence of a universal character as already described for P. falci-
parum (5, 37) and tetanus toxin peptides (31). On the other
hand, peptides LS1.6 and LS1.7 were poorly recognized in both
mice and humans. Our results with LS1.7 in humans are in
contrast with the earlier finding that LS1.7 peptide (amino
acids 1888 to 1909) was recognized by more than 75% of hu-
man donor PBMC from an area of endemicity in Papua New
Guinea (mean SI: 7.2) (11). This is surprising, and it is not
clear to us if this is due to parasite strain variations or to vari-
ations in exposure to malaria and genetic background of the
population in question.
IFN-g is the most potent cytokine known to act upon P. fal-
ciparum liver schizogony in vitro (27). The inhibiting effect of
IFN-g on liver stages in both primate and rodent models has
already been observed (12, 27). We also found that PfLSA-1-
based peptides induce antigen-specific IFN-g secretion by PBMC
in a large proportion of individuals. However, here again the
IFN-g levels did not always correlate with the lymphocyte
proliferation data. This lack of correlation between IFN-g pro-
duction and T-cell proliferation with malarial antigens has
been observed earlier by us and several other workers (11, 14,
20, 22).
It is generally believed that identification of T-cell epitopes
capable of eliciting an immune response in individuals of dif-
ferent genetic backgrounds would be necessary for designing a
subunit vaccine. In the present study, we have defined immu-
nodominant TH-cell epitopes commonly recognized by murine
T cells and PBMC from a large proportion of malaria-exposed
humans with diverse genetic backgrounds. Other studies have
FIG. 6. Antibody responses in human subjects exposed to P. falciparum ma-
laria. Human serum samples were diluted to 1:200 and used in ELISA to detect
antibody levels against PfLSA-1-derived peptides. The positive responders were
defined as those who had ODs above the mean plus 2 SD of 10 normal control
sera. The cutoff OD for each peptide is indicated in Materials and Methods.
TABLE 3. Synoptic summary of immune responses in 22
P. falciparum-exposed human subjects against
PfLSA-1-derived T- and B-cell epitopes
PfLSA-1-derived
peptide
% Positive responders
B-cell response T-cell response IFN-g secretion
LS1.1 40.9 59.0 45.4
LS1.2 72.7 59.0 53.3
LS1.3 36.3 45.4 40.0
LS1.4 31.8 40.0 40.0
LS1.5 27.2 27.2 36.3
LS1.6 22.7 13.6 22.7
LS1.7 13.6 13.6 18.1
LS1R 59.0 18.1 31.8
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also shown that T-cell epitopes from vaccine target antigens of
P. falciparum are commonly recognized by both murine and
human T cells (5, 37). Given the large number of peptide se-
quences from different vaccine target antigens that may have to
be assessed and the difficulties in collecting blood samples
sufficient for these assays from the infected patients, this strat-
egy may be an alternative even though there may be an inher-
ent risk of missing some epitopes.
The antibody response to PfLSA-1 during the course of
natural infection has been investigated earlier, and several
B-cell epitopes have been characterized (11, 20). Our results of
ELISA with synthetic peptides showed that most of the pre-
dicted T-cell epitope sequences also reacted with P. falcipa-
rum-exposed Indian sera. The greatest response was obtained
with peptide LS1.2, which reacted with more than 60% of the
serum samples, followed by LS1.3. Notably, LS1.2 and LS1.3
also represented dominant human T-cell epitopes, suggesting
that such peptide sequences may be good candidates to be
included in multiple-epitope-based polypeptide vaccine con-
structs. Likewise, our results have also suggested that peptides
LS1.1, LS1.4, and LS1.5 represent reasonably dominant B- and
T-cell epitopes in PfLSA-1. A sequence within peptide LS1.3
was found to be associated with resistance to severe malaria
(18), and the sequences overlapping with the peptides LS1.1
and LS1.5 have also been defined as immunodominant T-cell
epitopes in earlier studies (11, 24). The results of the present
study have further supported these findings. On the other
hand, our results have shown that peptides LS1.2 and LS1.4
represent newly identified TH epitopes, which have not been
described earlier. The repeat-based peptide LS1R reacted to
only 31.1% of malaria-exposed donors, in comparison to the
results of a previous study, where this peptide was shown to be
recognized by 75% of P. falciparum-exposed human sera (20).
In conclusion, our study has revealed the widespread immu-
nogenicity of PfLSA-1-derived synthetic peptides in murine
models and malaria-exposed human subjects and only a very
limited cross-recognition of PfLSA-1-based peptides by P. berg-
hei sporozoite-sensitized T cells in rodent malaria models. The
ability of a peptide epitope to bind and to be presented in the
context of several DR molecules reflects a broad major histo-
compatibility complex promiscuous binding pattern. The pos-
sibility of the presence of promiscuous epitopes in the con-
served regions of the PfLSA-1 protein may be of the utmost
importance in malaria vaccine development. Our results also
indicate that synthetic peptides which represent T-cell epitopes
in the murine model also by and large are responsive in human
subjects as T-cell determinants. It may therefore be desirable
or necessary to first assess the immunogenicities of synthetic
peptides in murine models in order to narrow down the num-
ber of peptides to a more manageable size for studies in hu-
mans exposed to the infectious agents.
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